Respiratory inhaler firm Vectura says it has narrowed full-year losses and received a $7.5m milestone payment from Novartis after its Swiss partner started phase III clinical tests of a combination lung drug.Novartis is using its QAB149, or indacaterol, with the UK firm's NVA237 in an effort to treat chronic obstructive pulmonary disease (COPD), or chronic bronchitis. "The data from the two Phase II QVA149 studies...were very encouraging and demonstrated the benefit of combining two potent bronchodilators in a convenient once-daily therapy with an attractive efficacy and safety profile," said Vectura CEO Chris Blackwell."This is the first once daily LAMA/LABA combination product to enter Phase III trials and, with an anticipated filing date of 2012, could provide an important future addition to the available treatment options for COPD." Separately, Vectura reported strong revenue growth during the 12 months ended 31 March, with total expected revenue of £28m-£42m, a 25% increase on the year before.Research and development expenditure is reckoned to be in the range of £34m-£38m and cash of about £64m, while the loss after tax should be "significantly" less than last year's £16.7m."These results demonstrate our continued focus on the financial goal of becoming a sustainably cash-generative business following receipt of substantial milestone and royalty revenues from our partnered late-stage respiratory programmes," said Blackwell. Final results are scheduled for 7 June.